A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

• Status: RECRUITING
• Trial end date: 2027-07-15

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

• Phase: PHASE1

Details

• Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• Collaborator: Celgene Corporation
• Treatments: Cyclophosphamide; fludarabine